

# Anti-Cyclin D1, Rabbit Monoclonal Antibody

Rabbit Monoclonal Antibody Catalog # ABV11823

## **Product Information**

Application	WB, IHC
Primary Accession	<u>P24385</u>
Reactivity	Human
Host	Rabbit
Clonality	Monoclonal
Isotype	Rabbit IgG
Calculated MW	33729

# **Additional Information**

Gene ID	595
Positive Control Application & Usage Alias Symbol Other Names	WB: Hela cell lysate; IHC: human breast cancer tissue IHC: 1:500 -1:1000 dilution; WB: 1:1000 - 1:2000 dilution. CCND1 G1/S-specific cyclin-D1, B-cell lymphoma 1 protein, BCL-1, PRAD1
Appearance	Colorless liquid
Formulation	In 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide
Reconstitution & Storage	-20 °C
Background Descriptions Precautions	Anti-Cyclin D1, Rabbit Monoclonal Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

#### **Protein Information**

Name	CCND1 {ECO:0000303 PubMed:8204893, ECO:0000312 HGNC:HGNC:1582}
Function	Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed: <u>1827756</u> , PubMed: <u>1833066</u> , PubMed: <u>19412162</u> , PubMed: <u>33854235</u> , PubMed: <u>8114739</u> , PubMed: <u>8302605</u> ). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase (PubMed: <u>1827756</u> , PubMed: <u>1833066</u> , PubMed: <u>19412162</u> , PubMed: <u>8114739</u> , PubMed: <u>8302605</u> ). Hypophosphorylates RB1 in early G(1) phase (PubMed: <u>1827756</u> ,

PubMed:<u>1833066</u>, PubMed:<u>19412162</u>, PubMed:<u>8114739</u>, PubMed:<u>8302605</u>). Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals (PubMed:<u>1827756</u>, PubMed:<u>1833066</u>, PubMed:<u>19412162</u>, PubMed:<u>8302605</u>). Also a substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity (PubMed:<u>15241418</u>). Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (PubMed:<u>9106657</u>). Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner (PubMed:<u>16569215</u>, PubMed:<u>18417529</u>).

#### **Cellular Location**

Nucleus. Cytoplasm. Nucleus membrane. Note=Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members

### Background

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G1/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G1 phase. Hypophosphorylates RB1 in early G1 phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.

#### Images



Immunohistochemical staining of formalin fixed and paraffin embedded human breast cancer tissue sections using anti-Cyclin D1 monoclonal antibody at 1:1000 dilution.

Western blot of Hela cell lysates using anti-Cyclin D1 monoclonal antibody at 1:1000 dilution, showed a band of Cyclin D1 (~34kDa) expressed in Hela cells.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.